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ABSTRACT
Itaconic acid is produced by mammalian leukocytes upon pro-inflammatory 
activation. It appears to inhibit bacterial growth and to rewire the metabolism of 
the host cell by inhibiting succinate dehydrogenase. Yet, it is unknown whether 
itaconic acid acts only intracellularly, locally in a paracrine fashion, or whether it is 
even secreted from the inflammatory cells at meaningful levels in peripheral blood 
of patients with severe inflammation or sepsis.
The aim of this study was to determine the release rate of itaconic acid from 
pro-inflammatory activated macrophages in vitro and to test for the abundance of 
itaconic acid in bodyfluids of patients suffering from acute inflammation.
We demonstrate that excretion of itaconic acid happens at a low rate and that it 
cannot be detected in significant amounts in plasma or urine of septic patients or in 
liquid from bronchial lavage of patients with pulmonary inflammation.
We conclude that itaconic acid may serve as a pro-inflammatory marker in 
immune cells but that it does not qualify as a biomarker in the tested body fluids.
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INTRODUCTION
Recent reports have suggested itaconic acid (IA) 
to be a novel metabolic biomarker [1]. This suggestion 
is based on its intracellular identification in activated 
pro-inflammatory macrophages [2, 3] and the detection 
of IA in the plasma of pregnant women who developed 
diabetes mellitus after birth compared to controls not 
progressing to overt diabetes mellitus [1]. IA is a metabolic 
product derived from the tricarboxylic acid (TCA) cycle 
intermediate cis-aconitic acid, catalysed by cis-aconitate 
decarboxylase (IRG1/CAD). Two physiological functions 
of IA have been described in pro-inflammatory cells: (1) 
IA shows antibacterial properties by inhibiting bacterial 
isocitrate lyase, an enzyme of the glyoxylate shunt, giving 
microorganisms a survival advantage at carbohydrate 
limiting conditions [2, 4] and (2) IA inhibits succinate 
dehydrogenase (SDH) in the host cell to induce metabolic 
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rewiring during pro-inflammatory activation [5, 6]. 
Hence, IA plays a dual complementary role by triggering 
metabolic adaptation of the host cell and by inhibiting 
growth of invading pathogens. It has been reported that IA 
is hardly detectable in quiescent macrophages but increases 
to millimolar concentrations upon pro-inflammatory 
activation within a few hours post-activation to a maximum 
level at ten hours post-activation [2, 6]. 
It has also been reported that IA is released from pro-
inflammatory macrophages [6–8]. These reports suggest 
that IA might also be detectable in the blood of patients 
with bacterial sepsis and thus may possibly qualify as an 
early biomarker in a clinical setting. However, absolute 
quantifications of IA are so far lacking and the potential 
effects of extracellular IA are unclear to date [9]. 
To test the hypothesis if IA might be an early sepsis 
marker, we quantified IA in the extracellular space of 
macrophages in vitro and analysed different body fluids 
of septic patients.
RESULTS
IA release rates in vitro
To quantify IA released from lipopolysaccharide 
(LPS) activated macrophages in vitro, we used the mouse 
macrophage cell line RAW 264.7 and murine bone 
marrow derived macrophages (BMDM), activated the 
cells with 10 ng/ml LPS and analysed the medium for the 
presence of IA. We determined an average extracellular 
concentration of 9 µM for RAW 264.7 and 5 µM for 
BMDMs, respectively (Figure 1A–1C). Given the number 
of viable cells we estimated an average net release rate 
of 2.34 fmol/cell/h in the case of RAW264.7 cells and 
0.53 fmol/cell/h in the case of BMDMs (Table 1). The 
determined differences in release rates are in line with the 
quantified intracellular IA concentrations (8 mM for RAW 
264.7 cells [2] and 1.5 mM for BMDMs, respectively 
(Table 1)). Assuming passive diffusion as the main 
driving force for extracellular IA accumulation, higher 
intracellular concentrations result also in higher medium 
concentrations after LPS stimulation. 
Analysis of patient derived samples
The specific production of IA upon pro-
inflammatory stimuli as well as the release of IA prompted 
us to test whether IA may potentially be measured in body 
fluids of septic patients or in patients with suspected 
progression of occult systemic bacterial infection to overt 
sepsis. In this case IA could represent a novel biomarker 
to improve to the existing clinical and laboratory portfolio 
for inflammation assessment.
Therefore, we analysed blood and urine samples of 
different sepsis patients (Table 2), bronchoalveolar lavage 
fluids (BALF) of patients with different lung diseases 
including bacterial infection or exacerbation of chronic 
pulmonary disease (Table 3).
For the analysis, we first determined the limit of 
quantification (LOQ) for IA in plasma with our analytical 
pipeline, using gas chromatography coupled to mass 
spectrometry (GC-MS). With 1 µM (Figure 2A) the LOQ 
in plasma was higher compared to medium (Figure 1A) 
but reasonable, since the high protein content of plasma 
may bind a significant fraction of available metabolites, 
resulting in low recovery of IA. Then, we applied our 
analysis pipeline to screen the collected body fluids for 
IA. We did not detect any signal for IA in any of the body 
fluids, except for one single patient where we detected a 
low signal below the limit of quantification in the urine. 
Figure 1: Quantification of itaconic acid concentration in cell culture medium upon LPS stimulation. (A) External 
calibration curve (concentration range: 0.01–12.5 µM) for absolute quantification of IA in cell culture medium. (B–C) IA concentration 
(µM) in cell culture media of RAW264.7 (B) mouse macrophages and BMDMs (C) 6 h after stimulation (LPS) with 10 ng/ml LPS or 
of untreated cells (Ctrl). Each data point indicates one independent experiment with triplicate wells (2 experiments in (B) and three 
experiments in (C)). Data is represented as mean ± SEM.
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However, we did not detect a signal in the respective 
plasma sample. Interestingly, this patient was suffering 
from a genitourinary tract infection and urosepsis.
To cross validate our results we employed a set of 
commercial sepsis samples comprising four plasma and four 
serum samples (Table 4). Also in these samples, all values 
were close to, or below the detection limit (Figure 2B). As 
a positive control we also measured lactate concentrations, 
a metabolite that is known to be increased under septic 
conditions. As expected, both serum and plasma samples 
had significantly increaseed lactate concentrations 
compared to respective controls (Figure 2C–2E). 
Intrigued by the one urine sample where we 
observed at least a low IA signal, we further investigated 
if patient derived cells contain IA and thus, locally, 
leukocytes might increase IA concentrations by low 
excretion rates. To that end, we analysed the cell pellets 
obtained from the bronchial lavages. In patients with 
severe lung infections, leukocytes migrate into the 
alveoli and are aspirated during the lavage. These cells 
were pelleted during sample processing and snap frozen. 
Intracellular metabolites of these pellets were extracted 
and analysed with GC-MS. In most of these samples we 
could detect low abundant signals for IA and we observed 
Table 1: Intracellular concentration of IA and release rates upon LPS activation
 Conc [mM] Release [fmol/cell/h]
RAW 8 [2] 2.34
BMDM 1.51 0.53
The concentration in RAW cells is derived from [2]. Release rates were determined based on medium concentration 
(Figure 1), viable cells and time after LPS activation.
Table 2: Sepsis patient overview
Gender Age Type of Infection Leu CRP PCT Type and duration of Therapy
M 60 Unclear 8.7 117 8.7 Fortum and Tygacil 5th day
M 75 Retention pneumonia 14.3 101 1.6 Tazobac, Meronem 2nd day
M 57 Pancreatitis and Pneumonia 6.8 390 16.6 Tazobac, Tavanic 2nd day
M 71 Pneumonia (repeated sepsis) 9.4 133 1.1 Vancomycin, Meronem 1st day
M 64 Aspiration pneumonia, 13.9 332 2.5 Vancomycin, Meronem 1st day
M 57 Endocarditis, pneumonia 18.9 377 2.1 Zyvoxid, Eremfat 1st day, Clont 3rd day
M 57 Pneumonia 9 111 1.1 Tazobac, Tavanic 1st day
M 73 Retention pneumonia, STEMI 7.4 130 2.4 Tazobac, Tavanic 2nd day
M 59 Retention pneumonia, cardiogenic shock 11 234 3.5 Vancomycin, Meronem 1st day
M 57 Pneumonia ARDS 18.7 81 2.4 Maxipime, Vancomycin 4th day
M 86 Retention pneumonia 17.7 173 1.4 Vancomycin, Meronem 2nd day
M 66 Urosepsis 22 402 122 Tazobac, Tavanic 2nd day
M 70 Retention pneumonia 19.5 188 1.3 Vancomycin, Meronem 2nd day
F 85 Pneumonia (aspiration pneumonia) 7.1 208 4.8 Tazobac, Tavanic 4th day
M 77 Pneumonia, infected hematoma 10.8 315 2.2 Vancomycin, Meronem 2nd day
M 68 Pneumonia 14.2 211 9.1 Vancomycin, Meronem, Clont 2nd day
M 66 Aspiration pneumonia 10.5 149 5.6 Tazobac, Tavanic 2nd day
M 55 Retention pneumonia during cardiogenic shock 19.6 270 4.7 Tazobac, Cubicin 2n day
F N/A Urosepsis 20.9 201 262 Vancomycin, Meronem 1st day
Healthy individuals served as controls. PCT: pro-calcitonin; CRP: c-reactive protein.
Oncotarget32101www.oncotarget.com
a significant correlation (R2 = 0.39; p-value = 0.016) with 
the C-reactive protein (CRP) values (Figure 3, Table 3), 
indicating that systemic inflammation correlates with 
the detected IA signals. Hence, it might be possible that 
locally, IA concentrations in the microenvironment are 
increased as a result of low excretion rates.
DISCUSSION
In this study we profiled IA release rates from 
macrophages in vitro and we analysed different body fluids 
of patients suffering from acute sepsis to test if IA might 
accumulate to sufficient concentrations in the circulation. 
The latter case would mean that IA could potentially serve 
as a novel biomarker in clinical settings to detect systemic 
bacteremia [10]. A novel metabolic biomarker detectable 
in the plasma could be an asset to the existing clinical and 
laboratory portfolio for sepsis assessment, since a precise 
diagnosis for acute sepsis, especially at an early stage, is 
still challenging [11]. Using marker metabolites in blood 
samples as biomarkers is of high interest due to the ease 
of accessibility and availability in clinical settings. A well-
known example is the oncometabolite 2-hydroxyglutarate 
(2HG), which can be used as a biomarker in isocitrate 
dehydrogenase (IDH) mutated acute myeloid leukemia 
(AML) and intrahepatic cholangiocarcinoma (ICC) patients 
[12, 13]. Due to its rapid production upon extracellular 
pro-inflammatory stimuli, IA could theoretically qualify 
as an early biomarker, helping to identify minimal 
systemic inflammatory responses similar or even superior 
to pro-calcitonin [14]. A similar hypothesis has recently 
been raised in the context of rheumatoid arthritis [15]. 
However, we were not able to detect elevated IA levels in 
the analysed body fluids from septic patients. Therefore, 
IA does not seem to be a suitable biomarker of systemic 
inflammation employing standard routine laboratory 
methodology.
Our result is in contrast to the previous report by 
de Seymour et al. [1], who reported IA as a biomarker 
in peripheral blood of pregnant women who progressed 
to overt diabetes mellitus post partum. The reason for 
this discrepancy in detecting IA in peripheral blood 
remains unclear and might be at best caused by different 
technology being applied for detection. However, our 
results clearly indicate that in a clinical setting, IA is not 
detectable with a standard (but state-of-the-art) analytical 
infrastructure even in septic conditions. This observation 
is corroborated by the fact that there is, to our knowledge, 
no other report of increased IA concentrations, neither in 
sepsis nor other patient cohorts.
The low concentrations of IA in the circulation 
are supported by the very low excretion rates that we 
determined in our in vitro experiments. Despite high 
intracellular IA concentrations in the mM range we only 
observed very low release rates. As a comparison, the 
extracellular lactate concentration in similar experiments 
with RAW 264.7 cells has been reported to be 20 mM, 
resulting in a net release rate of 170 fmol/cell/h [16], 
indicating that the release of IA into the extracellular space 
happens at a low rate. 
The IA concentration in the tissue culture media 
might also be explained by accumulative release from 
apoptotic cells or by lysosomal trafficking and fusion with 
the plasma membrane. However, the latter mechanism 
Table 3: Patient overview bronchial lavage samples
gender Age leucocytes (G/L) CRP (mg/L) pathology
f 56 11,80 42,30 pulmonary abscess
m 67 6,60 26,30 interstitial nephritis
m 44 6,40 9,80 pneumonia
m 63 8,30 3,30 COPD
f 44 14,20 1,70 bronchogenic cyst
m 54 24,50 5,60 hemoptysis
f 52 2,10 17,80 adenocarcinoma
f 27 8,90 n.a. sarcoidosis
f 62 6,60 1,20 adenocarcinoma
m 77 6,40 4,50 adenocarcinoma
f 62 10,00 3,10 small cell lung cancer
m 69 1,04 32,90 mesothelioma
f 69 7,20 8,90 small cell lung cancer
f 69 n.a. n.a. chronic cough
m 74 7,90 24,00 pneumonia
f 77 7,80 23,10 adenocarcinoma
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alone is not sufficient to reach the measured concentration 
in our in vitro experiments, suggesting that the detected IA 
might be a net result of both, diffusion and release from 
vesicles and apoptotic cells. As an alternative to release, 
IA might be further metabolised within the cell although a 
mammalian metabolic degradation pathway for IA has so 
far only been described for the liver [17, 18]. To provide 
detailed explanation on these possibilities, further work is 
required in the future.
The notion that IA is mainly intracellularly abundant 
and not actively excreted is supported by our observation 
that we could not detect IA in the liquids of BALF’s but in 
intracellular extracts of BALF derived cell pellets. 
When analysing the intracellular extracts, we even 
observed a correlation between the measured IA signal 
and the determined CRP values. These data suggest that 
the higher IA signals originate from the intracellular 
space of the leukocytes associated with the increased 
CRP. We can speculate that this specific observation also 
applies to the recorded signal in the urine of the urosepsis 
patient where the IA signal likely derived from apoptotic 
leukocytes in urine.
Based on the low excretion rates, a paracrine effect 
in the microenvironment is still debatable. But due to its 
chemical properties as a charged molecule IA can hardly 
cross the plasma membrane, which is why in in vitro 
experiments extracellular IA is applied in the mM range to 
cross the plasma membrane and/or membrane permeable 
dimethylIA is used [5, 6]. In terms of potential antibacterial 
properties in the extracellular space, IA concentrations 
are most probably orders of magnitude too low to inhibit 
bacterial growth [2]. Required concentrations in the mM 
range are most likely only possible to appear within the 
cells. We still cannot exclude that IA may have distinct 
Figure 2: Quantification of itaconic acid and lactic acid in serum and plasma samples of sepsis patients. (A) External 
calibration curve (concentration range: 0.01–10 µM) for absolute quantification of IA in plasma and serum. (B) Quantification of IA in 
four plasma and four serum samples of sepsis patients with respective healthy control samples. For background subtraction the determined 
average IA concentration of control samples was subtracted of the determined concentrations of the sepsis samples. Each sample was 
analysed in three technical replicates. *indicates samples with IA concentrations below the detection limit. (C–D) Quantification of lactate 
in the same samples as in (B) and (E) respective fold change increase of lactate in sepsis samples compared to respective controls. Data 
(A–D) is represented as mean ± SD.
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effects involving the activation of so far unknown 
signalling pathways or facilitating receptor activation. An 
example for such a metabolite derived activation, with 
similar chemical structure, is given by succinate activating 
GPR91 to promote stem cell migration [19]. However, at 
this point testing such hypotheses are beyond the scope 
of the present manuscript. Our data support primarily the 
notion that IA acts as a cell intrinsic factor to inhibit SDH 
in the host cell and potentially, to support bacterial killing 
in lysosomes by inhibiting the glyoxylate shunt. 
To reach a translational pre-clinical stage it will be 
important to evaluate if and how IRG1/CAD and IA could 
be exploited to treat inflammatory diseases in humans 
rather than serving as biomarkers. 
In summary, our results indicate that IA may rather 
acts as a local antimicrobial metabolite. It does not represent 
a suitable biomarker to be used in a clinical setting.
MATERIALS AND METHODS
Cell culture
RAW 264.7 mouse leukaemic cells 
(ATCC®TIB-71™) were cultured as described in detail 
in [16]. Briefly, cells were cultured in DMEM D5796 
supplemented with 10% FBS. Macrophages (BMDM) 
were differentiated from bone marrow of wild type 
mice: Bone marrow was flushed and isolated using ice-
cold PBS. Cells were then cultured in DMEM D5796 
supplemented with 10% FBS, 10% M-CSF and 0.5% Pen/
Strep. At day 5, adherent macrophages were collected by 
scraping, counted and seeded for experiment. LPS (from 
E.coli, Sigma L6529) was prepared as a working stock 
of 1 μg/mL in DMEM and spiked 1:100 into the wells of 
the culture dish for a final concentration of 10 ng/mL. For 
cell counting and assessment of cell viability a Vi-Cell™ 
XR (Beckman Coulter) automated cell counter was used 
according to the manufacturer’s instructions.
Metabolite extraction from medium, 
derivatisation, and GC-MS measurement
The method was adopted from [20] with the 
following changes: Extracellular metabolites from culture 
medium samples were extracted in triplicate using a 
methanol/water mixture (5:1, v/v). The water fraction 
contained the internal standard (IS) Pentanedioic acid-D6 
(c = 10 µg/mL; C/D/N Isotopes Inc.). 40 µL of medium 
were added to 240 µL of the ice-cold methanol/water+IS 
mixture (5:1, v/v). After adding 100 µL ice-cold chloroform, 
the mixture was vortexed for 10 min at 4° C and 2,000 rpm 
(Eppendorf Thermomixer C). For phase separation, 100 µl 
of chloroform and 100 µl of water were added and vortexed 
for 1 min at 4° C and 2,000 rpm. Then, the mixture was 
centrifuged at 21,000 × g for 5 min at 4° C. 250 µL of 
the polar (upper) phase were transferred to GC glass vial 
with micro insert (5–250 µL) and evaporated to dry under 
vacuum at −4° C.
For absolute metabolite quantification, a dilution 
series of IA was included in the extraction procedure and 
measured in triplicate. The stock solution (c = 20 mM) was 
freshly prepared by dissolving IA in water. It was used for the 
preparation of an external calibration curve in DMEM D5796 
with 10% FBS medium with the following concentration 
levels: 0.01; 0.05; 0.1; 0.5; 1; 5; 10 and 12.5 µM.
Metabolite derivatisation was performed by using 
a multipurpose sampler (Gerstel). Dried medium extracts 
were dissolved in 15 µL pyridine, containing 20 mg/ml 
methoxyamine hydrochloride (Sigma-Aldrich), at 55° C 
for 90 min under shaking. After adding 15 µL MTBSTFA + 
Figure 3: Correlation analysis of CRP and IA signals in cell pellets of BALF’s. Each dot indicates one patient (n = 14). p value 
was calculated using linear regression. 
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1% TBDMSCI (Restek), samples were incubated at 55° C 
for 60 min under continuous shaking.
GC-MS analysis was performed by using an 
Agilent 7890A GC coupled to an Agilent 5975C inert 
XL Mass Selective Detector (Agilent Technologies). A 
sample volume of 1 µL was injected into a Split/Splitless 
inlet, operating in split mode (10:1) at 270° C. The gas 
chromatograph was equipped with a 30 m (I.D. 0.25 mm, 
film 0.25 µm) DB-35MS capillary column (Agilent 
J&W GC Column). Helium was used as the carrier gas 
with a constant flow rate of 1.4 mL/min. The GC oven 
temperature was held at 100° C for 1 min and increased to 
200° C at 8° C/min. Then, the temperature was increased 
to 325° C at 50° C/min and held for 6 min. The total run 
time was 22 min. The transfer line temperature was set to 
280° C. The MSD was operated under electron ionization 
at 70 eV. The MS source was held at 230° C and the 
quadrupole at 150° C. For precise quantification, GC-MS 
measurements were performed in selected ion monitoring 
(SIM) mode using the following masses: m/z 301.2; 343.2; 
358.2 (dwell times: 60 ms) for itaconic acid and m/z 
235.2; 309.2; 351.3 (dwell times: 75 ms) for Pentanedioic 
acid-D6.
Metabolite extraction from plasma, serum and 
urine, derivatisation, and GC-MS measurement
200 µL urine were centrifuged at 400 × g for 5 min 
at 4° C. 100 µL supernatant were mixed with 75 µL urease 
(5 mg/mL in HEPES, c = 25 mM, pH: 7,0). The mixture 
was kept for 5 min at 37° C. 15 µL were mixed with 
135 µL of methanol/water mixture (8:1, v/v). The mixture 
was vortexed for 5 min at 4° C and 1,400 rpm (Eppendorf 
Thermomixer). Then, the mixture was centrifuged at 
21,000 × g for 5 min at 4° C. 30 µL were transferred to a 
GC glass vial with micro insert (5–250 µL) and evaporated 
to dry under vacuum at –4° C.
For plasma and serum extraction, 15 µL of plasma 
or serum were mixed with 135 µL of methanol/water 
mixture (8:1, v/v) including internal standard Pentanedioic 
acid-D6 (c = 2 µg/mL). Further processing was identical to 
the urine samples. For commercial sepsis samples, 60 µL 
were transferred to a GC glass vial with micro insert and 
evaporated to dry under vacuum at –4° C.
Metabolite derivatisation was performed by using 
a multipurpose sampler (Gerstel). Dried medium extracts 
were dissolved in 15 µL pyridine, containing 20 mg/mL 
methoxyamine hydrochloride (Sigma-Aldrich), at 40° C 
for 60 min under shaking. After adding 15 µL MSTFA 
(Macherey-Nagel), samples were incubated at 40° C for 
30 min under continuous shaking.
GC-MS analysis was performed by using an Agilent 
7890A GC coupled to an Agilent 5975C inert XL Mass 
Selective Detector (Agilent Technologies). A sample 
volume of 1 µL was injected into a Split/Splitless inlet, 
operating in splitless mode (plasma split mode 10:1) at 
270° C. The gas chromatograph was equipped with a 30 m 
(I.D. 250 µm, film 0.25 µm) DB-35MS capillary column 
(Agilent J&W GC Column). Helium was used as the carrier 
gas with a constant flow rate of 1.2 mL/min. The GC oven 
temperature was held at 80° C for 1 min and increased 
to 320° C at 15° C/min and held for 8 min. The total run 
time was 25 min. Plasma: 90° C for 1 min, 9° C/min 
to 270° C, 25° C/min to 320° C. Held for 7 min. The total 
run time was 30 min. The transfer line temperature was 
set to 280° C. The MSD was operated under electron 
ionization at 70 eV. The MS source was held at 230° C and 
the quadrupole at 150° C. For precise quantification, GC-
MS measurements were performed in SIM mode using the 
following masses: m/z 215.1; 230.1; 259.1 (dwell times: 
50 ms) for Itaconic acid and m/z 206.1; 239.1; 267.1 
(dwell times: 50 ms) for Pentanedioic acid-D6.
Metabolite extraction from bronchioalveolar 
lavage fluid (BALF), derivatisation, and GC-MS 
measurement
For BALF extraction, 15 µL of BALF were 
mixed with 135 µL of methanol/water mixture (8:1, 
v/v) including internal standard Pentanedioic acid-D6 
Table 4: Overview commercially obtained blood samples of septic patients
Product ID Matrix Age Gender Ethnicity Type of Infection
KH17_11267 K2 EDTA Plasma 86 M White
Beta-hemolytic streptococci group 
G
KH17_11835 K2 EDTA Plasma 84 F White E.coli
KH17_12100 K2 EDTA Plasma 65 F White H.influenza
KH17_12101 K2 EDTA Plasma 69 F White Klebsiella pneumoniae
KH17_2738 Serum 82 F White E.coli
KH17_4848 Serum 45 M White Klebsiella pneumoniae
KHBR_0600 Serum 42 M Black Staph haemolyticus
KH17_4596 Serum 53 M Black Staph epidermidis
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(c = 2 µg/mL). The mixture was vortexed for 5 min at 
4° C and 1,400 rpm (Eppendorf Thermomixer). Then, the 
mixture was centrifuged at 21,000 × g for 5 min at 4° C. 
60 µL were transferred to a GC glass vial with micro insert 
and evaporated to dry under vacuum at −4° C.
Metabolite derivatisation was performed by using 
a multipurpose sampler (Gerstel). Dried medium extracts 
were dissolved in 15 µL pyridine, containing 20 mg/mL 
methoxyamine hydrochloride (Sigma-Aldrich), at 55° C 
for 90 min under shaking. After adding 15 µL MTBSTFA 
+ 1% TBDMSC (Restek), samples were incubated at 55° C 
for 60 min under continuous shaking.
GC-MS analysis was performed by using an 
Agilent 7890A GC coupled to an Agilent 5975C inert 
XL Mass Selective Detector (Agilent Technologies). A 
sample volume of 1 µL was injected into a Split/Splitless 
inlet, operating in splitless mode at 270° C. The gas 
chromatograph was equipped with a 30 m (I.D. 0.25 mm, 
film 0.25 µm) DB-35MS capillary column (Agilent 
J&W GC Column). Helium was used as the carrier gas 
with a constant flow rate of 1.2 mL/min. The GC oven 
temperature was held at 100° C for 2 min and increased 
to 300° C at 10° C/min. Then, the temperature was held 
for 4 min. The total run time was 26 min. The transfer line 
temperature was set to 280° C. The MSD was operated 
under electron ionization at 70 eV. The MS source was 
held at 230° C and the quadrupole at 150° C. For precise 
quantification, GC-MS measurements were performed in 
selected ion monitoring (SIM) mode using the following 
masses: m/z 301.2; 343.2; 358.2 (dwell times: 60 ms) for 
Itaconic acid and m/z 235.2; 309.2; 351.3 (dwell times: 
75 ms) for Pentanedioic acid-D6.
Metabolite extraction and intracellular itaconic 
acid quantification from BMDMs
Prior extraction, LPS-stimulated and non-stimulated 
BMDMs were washed with 0.9% NaCl. For intracellular 
metabolite extraction, 200 µL of ice-cold methanol and 
200 µL of water containing 1 µg/mL Pentanedioic acid-D6 
as internal standard were added and cells were scraped 
and transferred into a 1.5 mL reaction tube containing 
200 µl of chloroform. For intracellular Itaconic acid 
quantification by standard addition, aliquots of the water 
fraction (containing internal standard) were separately 
spiked with different concentrations of Itaconic acid 
(25; 50 and 100 µM) to extrapolate intracellular Itaconic 
acid levels. The mixtures were vortexed for 20 min at 
4° C and 1,400 rpm and centrifuged for 10 min at 4° C 
and 17,000 × g. 200 µL of the upper polar phase were 
transferred to a GC glass vial with micro insert and 
evaporated to dry under vacuum at –4° C. Derivatization 
and GC-MS measurement was performed as reported in 
section “Metabolite extraction from bronchioalveolar 
lavage fluid (BALF), derivatisation, and GC-MS 
measurement”.
Metabolite extraction from BALF cell pellets
For metabolite extraction from cells present in 
BALF, 200 µl ice-cold methanol, 200 µL water containing 
1 µg/mL Pentanedioic acid-D6 as internal standard and 
200 µL chloroform was added to the cell pellet and 
vortexed for 20 min at 4° C and 1,400 rpm. Then, the 
mixture was centrifuged for 10 min at 4° C and 17,000 × g 
and 250 µL of the upper polar phase were transferred to 
a GC glass vial with micro insert. Extracts were dried 
under vacuum at −4° C. Derivatization and GC-MS 
measurement was performed as described in section 
“Metabolite extraction from bronchioalveolar lavage fluid 
(BALF), derivatisation, and GC-MS measurement”.
Data normalisation and data processing
All GC-MS chromatograms were processed using 
MetaboliteDetector, v3.020151231Ra [21]. The software 
package supports automatic deconvolution of all mass 
spectra. Compounds were annotated by retention time 
and mass spectrum. The internal standard was added at 
the same concentration to every medium sample to correct 
for uncontrolled sample losses and analyte degradation 
during metabolite extraction. The data set was normalised 
by using the response ratio of the integrated peak area: 
analyte and the integrated peak area:_internal standard. 
Absolute concentrations were determined using the 
response ratios of the calibration curve of Itaconic acid as 
a function to quantify concentrations. 
Patient study
The cohort study was approved by the ethics 
committee of the state of Saarland, Germany (230/11) as 
well as the state research ethics committee of Luxembourg 
(201203/07). Patients or legal guardian were informed 
and asked for consent before sampling took place. Plasma 
and urine samples were collected from patients that were 
hospitalised for sepsis. Diagnosis was based on chart 
information (fever, c-reactive protein elevation CRP, 
evidence of bacteria in bloodstream, antibiotic treatment). 
Sampling procedures were incorporated into routine 
blood, urine or bronchial lavage examinations to avoid any 
extra stress to the subjects. Clinical information was taken 
from the chart. Blood and urine samples were immediately 
processed as described above. 
Commercial sepsis samples were purchased from 
Discovery Life Sciences (for sample details see Table 4). 
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